enhertu
(fam-trastuzumab deruxtecan-nxki)Daiichi Sankyo Inc.
Usage: ENHERTU is indicated for treating adult patients with unresectable or metastatic HER2-positive breast cancer, HER2-low or HER2-ultralow breast cancer, HER2-mutant non-small cell lung cancer, advanced HER2-positive gastric cancer, and unresectable HER2-positive solid tumors, all following prior systemic therapies.